Amgen Inc. (AMGN) Shares Sold by Adage Capital Partners GP L.L.C.
Adage Capital Partners GP L.L.C. lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,085,109 shares of the medical research company’s stock after selling 7,850 shares during the period. Adage Capital Partners GP L.L.C. owned about 0.14% of Amgen worth $165,099,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Highland Private Wealth Management acquired a new stake in Amgen during the first quarter valued at approximately $227,000. LPL Financial LLC raised its stake in Amgen by 2.0% in the first quarter. LPL Financial LLC now owns 157,187 shares of the medical research company’s stock valued at $24,041,000 after buying an additional 3,145 shares during the last quarter. Jones Financial Companies Lllp raised its stake in Amgen by 51.7% in the first quarter. Jones Financial Companies Lllp now owns 2,742 shares of the medical research company’s stock valued at $411,000 after buying an additional 934 shares during the last quarter. Bellevue Group AG acquired a new stake in Amgen during the first quarter valued at approximately $15,443,000. Finally, Orbis Allan Gray Ltd acquired a new stake in Amgen during the first quarter valued at approximately $11,536,000. 79.07% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded down 1.67% during midday trading on Friday, reaching $149.04. 5,159,413 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $157.92 and its 200 day moving average is $161.19. The firm has a market capitalization of $110.87 billion, a P/E ratio of 14.92 and a beta of 1.15. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.23. The business earned $5.81 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The company’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.72 earnings per share. On average, analysts expect that Amgen Inc. will post $11.56 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be given a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date of this dividend is Monday, November 14th. Amgen’s dividend payout ratio is presently 39.92%.
Several equities research analysts have commented on AMGN shares. Jefferies Group upped their price target on shares of Amgen from $187.00 to $198.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $206.00 price target on shares of Amgen in a report on Thursday, July 28th. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $193.00 price target on shares of Amgen in a report on Thursday, July 28th. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $192.00 price target on the stock in a report on Friday, July 29th. Finally, Argus reiterated a “buy” rating and issued a $195.00 price objective (up previously from $185.00) on shares of Amgen in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and a consensus price target of $182.04.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.